-
449 pharmaceutical companies in the first half of the year report card released! 21 companies have revenues of more than 10 billion yuan
Time of Update: 2022-09-14
2 billion yuan, Mindray Medical has exceeded 5 billion yuan, and Renfu Pharmaceutical, Jichuan Pharmaceutical, Kai Laiying and so on have broken 1 billion yuan for the first time; From the perspective of revenue, 21 companies exceed the scale of 10 billion yuan, and Shanghai Pharmaceutical ranks first; From the perspective of gross profit margin, 12 companies such as Maiwei Biology, Shenzhou Cell, and Wuwu Biology exceed 90%.
-
Local pharmaceutical companies have transformed this field, and the demand for "dressup" in the future is strong!
Time of Update: 2022-09-14
Compared with Western developed countries, China's biopharmaceutical industry started late, but in recent years, with the support of favorable policies and the continuous breakthrough of key technologies for the development and production of biological products, the domestic biomedical industry has ushered in rapid development and great growth potential.
-
NMPA: Pharmaceutical companies can participate in the revision of Chinese medicine standards in ten ways
Time of Update: 2022-09-14
(1) According to the research and development, production and quality control of traditional Chinese medicines, on the basis of continuously improving drug standards using scientific and advanced, economically reasonable technical methods, put forward suggestions or applications for the establishment of Chinese medicine standards that need to be formulated or revised to the State Pharmacopoeia Commission or the provincial drug supervision and management departments.
-
New progress in the adjustment of the medical insurance catalogue in 2022: more than 300 drugs passed the preliminary form review
Time of Update: 2022-09-14
【Pharmaceutical Network Industry Dynamics】 On September 6, the National Medical Security Bureau announced the list of drugs that passed the preliminary form review in 2022 for the adjustment of the national basic medical insurance, work injury insurance and maternity insurance drug list.
-
A new round of health care negotiations is like an arrow! Of the 490 medicines, 344 passed the preliminary form examination
Time of Update: 2022-09-14
【Pharmaceutical Network Industry News】On September 6, the National Medical Insurance Bureau has announced the list of drugs that have passed the preliminary form review in the adjustment of the nation
-
2022 Medical Insurance Directory Preliminary Review List Perspective: Novartis, Pfizer, Hengrui more than 10 products competition!
Time of Update: 2022-09-14
Judging from the preliminary list, there are Henlius Henlius' Slullimonumab Injection, Corning Jerry's Envolli Monoclonal Antibody Injection, and Kangfang Bio's Cadonilimonumab Injection shortlisted, which also means that Yuheng Biologics and CStone Pharmaceutical's PD-(L)1 products will undoubtedly not be eligible for this year's medical insurance catalog.
-
Domestic new crown oral drugs passed the preliminary form review of the adjustment of the medical insurance drug list in 2022
Time of Update: 2022-09-14
(End) China's National Medical Security Administration recently announced the drugs and related information that passed the preliminary formal review of the 2022 medical insurance drug list adjustment.
-
National Health Commission: The number of people insured by basic medical insurance in the country exceeds 1.36 billion
Time of Update: 2022-09-14
medical Li Bin mentioned that this decade is a decade in which the public health protection network is firmly woven and the prevention and control of infectious diseases, chronic diseases, occupational diseases and endemic diseases is more effective and powerful.
-
National Health Commission: The main goals of the Healthy China Action in 2022 will be achieved ahead of schedule
Time of Update: 2022-09-14
The Propaganda Department of the CPC Central Committee held a series of press conferences on the theme of "China's Decade" on the afternoon of September 7, and Li Bin, deputy director of the National
-
344 drugs passed the preliminary formal review of the 2022 National Medical Insurance Drug Catalogue, including the first domestic new crown oral drug
Time of Update: 2022-09-14
Drugs for children with tumor tumors in children In order to do a good job in the prevention and control of the new crown epidemic, the National Medical Insurance Bureau previously issued regulations to temporarily include relevant drugs in the "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia" into the scope of medical insurance payment, providing strong support for epidemic prevention and control.
-
The broad-spectrum anti-cancer drug with a monthly fee of 230,000 yuan passed the form review of the National Medical Insurance Bureau! CAR-T also passed
Time of Update: 2022-09-14
From the perspective of the reason for the choice, the National Medical Insurance Bureau said that lalotinib is the first drug approved for marketing in the world and China, with unlimited tumor species and accurate targeting of NTRK gene fusion, and there is no reference product in the current catalog, and there is no reference product in China.
-
With the rapid development of biomedicine, pharmaceutical machinery companies are accelerating the construction of biological engineering technology strength
Time of Update: 2022-09-14
In recent years, with the intensification of aging and the continuous enhancement of people's health awareness, the support of a series of favorable policies is promoting the rapid development of the
-
CanSino Biotech's first inhaled COVID-19 vaccine was approved for emergency use in China
Time of Update: 2022-09-14
A few days ago, CanSino bioinspiration with recombinant new coronavirus vaccine (type 5 adenovirus vector) Kwesa ® Wuyou ®, after the National Health Commission made a recommendation, the State Drug Administration organized and agreed to be included in the emergency use as a reinforcing needle.
-
More than 100 pharmaceutical companies have been rated, and institutions have paid close attention to the segments of traditional Chinese medicine and offline pharmacies
Time of Update: 2022-09-14
1% year-on-year; Achieved a net profit attributable to the mother of 576 million yuan, an increase of 14.
1% year-on-year; Achieved a net profit attributable to the mother of 576 million yuan, an increase of 14.
-
Sichuan shellfish price increase, production reduction caused by the disaster?
Time of Update: 2022-09-14
Pharmaceutical Sixth, the future market pre-judgment 1, the family planting Sichuan shellfish cycle is long, the input is large, the risk is high According to the 3-year growth cycle, a total investment of about 70,000-90,000 yuan is required.
-
In the first half of the year, public security organs cracked more than 1,500 illegal and criminal cases of manufacturing and selling counterfeit and inferior drugs
Time of Update: 2022-09-10
drugsand health of The reporter learned from the Ministry of Public Security on the 24th that since the beginning of this year, the public security organs across the country have closely combined the "100-day action" of summer public security to crack down on rectification, deeply promote the "Kunlun 2022" special action, and launch a fierce offensive against drug crimes such as the manufacture and sale of counterfeit and inferior drugs.
-
An international multi-center Phase II/III clinical study of zolitinib in the treatment of NSCLC with CNS metastasis completed the final visit of the last subject
Time of Update: 2022-09-10
Zolitinib is a next-generation EGFR-TKI drug designed for the treatment of advanced non-small cell lung cancer with CNS metastases, with the ability to completely penetrate the blood-brain barrier Top
-
Asieris Pharmaceuticals 2022 Semi-annual Report: Rapid clinical advancement worldwide, and steady implementation of the integrated commercialization strategy of diagnosis and treatment
Time of Update: 2022-09-10
Rapid advancement of core clinical projects, strengthening the global distribution of pipelines In the field of reproductive system diseases, APL-1702 (trade name: Sevita®), the core product of photodynamic therapy developed by Asieris, which integrates drugs and devices, has received international multi-center Phase III clinical trials in China, Hungary, Approved by national drug regulatory agencies of Ukraine, Germany, Slovakia, Czech Republic, Netherlands, Poland and other countries and enrolled patients, the enrollment of all subjects will be completed in July 2022 .
-
State Food and Drug Administration: 20 batches of comfrey and other drugs produced by 9 enterprises such as Zhengzhou Ruilong Pharmaceutical do not meet the regulations
Time of Update: 2022-09-09
The State Drug Administration requires the relevant provincial drug supervision and administration departments to organize a case filing and investigation of the suspected illegal acts of the above-mentioned enterprises and units in accordance with the Drug Administration Law of the People's Republic of China, and to disclose the results of the investigation and handling in accordance with regulations.
-
In the second half of the year, mergers and acquisitions of biopharmaceutical companies are expected to accelerate
Time of Update: 2022-09-09
In recent years, the enthusiasm for mergers and acquisitions of listed biopharmaceutical companies has been high .
In recent years, the enthusiasm for mergers and acquisitions of listed biopharmaceutical companies has been high .
